As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.
Jefferies highlights implications of weight loss drug GLP-1 on re/insurance sector - Reinsurance News
Obesity Cooking with Kathy Man
Universal diabetes drug coverage could be 'life-changing': doctor
20% of Americans Would Change Jobs to Gain Ozempic, Wegovy Coverage
GLP-1 Agonists Market Share, Size, Growth Insights 2030
Vernon Morning Star, August 29, 2014 by Black Press Media Group - Issuu
The cost of weight-loss drugs is putting some insurers off
As the market for new weight loss drugs soars, people with diabetes pay the price
www.usnews.com/dims4/USNEWS/2c0677c/2147483647/thu
Health Plan News Q1 2023
The official blog of PNHP - PNHP
The Ozempic Era of Weight Loss - The New York Times
GLP-1 Agonists Market Research Report 2023 - InsightAce Analytic
The Impact of GLP-1 Coverage and Spend on Pharmacy Benefits Costs - New
Tsunami of exclusion': Patients face aftermath of GLP-1 cuts
